Insider Selling: Hims & Hers Health (NYSE:HIMS) Insider Sells 4,150 Shares of Stock

Key Points

• Michael Chi, an insider at Hims & Hers Health, sold 4,150 shares at an average price of $56.00, totaling $232,400. This transaction represents a 1.47% decrease in his holdings.
• Hims & Hers Health's stock is currently trading at $50.32, reflecting a 1.1% decrease in value. The company has a market capitalization of $11.37 billion.
• The company's recent earnings report showed an EPS of $0.17, missing estimates, with quarterly revenue growth of 72.6% compared to the previous year, but less than analysts' expectations.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Michael Chi sold 4,150 shares of the stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $56.00, for a total transaction of $232,400.00. Following the transaction, the insider owned 278,654 shares of the company's stock, valued at approximately $15,604,624. The trade was a 1.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Michael Chi also recently made the following trade(s):

• On Thursday, July 24th, Michael Chi sold 2,100 shares of Hims & Hers Health stock. The shares were sold at an average price of $57.52, for a total transaction of $120,792.00.
• On Wednesday, July 23rd, Michael Chi sold 13,750 shares of Hims & Hers Health stock. The shares were sold at an average price of $56.00, for a total value of $770,000.00.

Hims & Hers Health Stock Down 1.1%

HIMS stock traded down $0.57 during trading on Wednesday, reaching $50.32. 26,813,251 shares of the company traded hands, compared to its average volume of 26,449,204. The business has a 50 day simple moving average of $50.40 and a 200 day simple moving average of $45.43. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98. The company has a market capitalization of $11.37 billion, a price-to-earnings ratio of 62.90, a price-to-earnings-growth ratio of 3.44 and a beta of 2.14. Hims & Hers Health, Inc. has a 12 month low of $15.73 and a 12 month high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The firm had revenue of $544.83 million for the quarter, compared to analysts' expectations of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The company's quarterly revenue was up 72.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.06 EPS. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Hims & Hers Health

Several institutional investors have recently made changes to their positions in HIMS. Centaurus Financial Inc. acquired a new stake in Hims & Hers Health during the 2nd quarter worth approximately $171,000. Thrivent Financial for Lutherans boosted its stake in Hims & Hers Health by 3.6% in the second quarter. Thrivent Financial for Lutherans now owns 46,444 shares of the company's stock worth $2,315,000 after purchasing an additional 1,617 shares in the last quarter. Marex Group plc acquired a new position in Hims & Hers Health in the second quarter valued at about $53,626,000. Nomura Holdings Inc. grew its holdings in shares of Hims & Hers Health by 151.4% during the second quarter. Nomura Holdings Inc. now owns 161,052 shares of the company's stock worth $8,028,000 after buying an additional 96,997 shares in the last quarter. Finally, Castleark Management LLC acquired a new position in Hims & Hers Health during the second quarter valued at approximately $2,921,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

HIMS has been the subject of several analyst reports. Zacks Research downgraded shares of Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 19th. UBS Group set a $30.00 price target on shares of Hims & Hers Health in a report on Monday, June 23rd. Citigroup reiterated a "sell" rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Truist Financial dropped their price objective on shares of Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating on the stock in a research note on Monday, August 18th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. Two analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have assigned a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Reduce" and an average target price of $38.92.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.